获得性耐药黑色素瘤细胞中DNA拓扑异构酶II活性及表达的调控
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
作者信息
Lage H, Helmbach H, Dietel M, Schadendorf D
机构信息
Institute of Pathology, Charité, Humboldt University Berlin, Germany.
出版信息
Br J Cancer. 2000 Jan;82(2):488-91. doi: 10.1054/bjoc.1999.0947.
Abstract
The role of DNA topoisomerases (Topo) IIalpha and IIbeta was investigated in various drug-resistant melanoma cells. Melanoma cells resistant to etoposide, exhibited an up to tenfold reduced Topo II activity corresponding to an increasing degree of drug resistance indicating that modulation of Topo II activity contribute to the drug-resistant phenotype. The reduction of Topo II activity was reflected by decreased nuclear amounts of both Topo II isoforms.
摘要
在各种耐药性黑色素瘤细胞中研究了DNA拓扑异构酶（Topo）IIα和IIβ的作用。对依托泊苷耐药的黑色素瘤细胞，其Topo II活性降低了多达10倍，这与耐药程度的增加相对应，表明Topo II活性的调节促成了耐药表型。Topo II活性的降低表现为两种Topo II亚型的核含量减少。
相似文献
1
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.获得性耐药黑色素瘤细胞中DNA拓扑异构酶II活性及表达的调控
Br J Cancer. 2000 Jan;82(2):488-91. doi: 10.1054/bjoc.1999.0947.
2
Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.细胞对药物暴露的适应性：耐药表型的演变
Cancer Res. 1997 Nov 15;57(22):5086-92.
3
4
5
Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.拓扑异构酶IIα和拓扑异构酶IIβ药物稳定的可裂解复合物的寿命差异及其与药物敏感性的关系。
Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. doi: 10.1007/s00280-003-0701-1. Epub 2003 Sep 23.
6
7
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.选择对DNA拓扑异构酶II催化抑制剂ICRF-187具有抗性的人白血病CEM细胞，会导致拓扑异构酶IIα水平升高，并改变G2/M期检查点和细胞凋亡反应。
Mol Pharmacol. 2000 Feb;57(2):296-307.
8
Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.多种机制赋予胰腺癌细胞不同的耐药表型。
J Cancer Res Clin Oncol. 2002 Jul;128(7):349-57. doi: 10.1007/s00432-002-0349-y. Epub 2002 Jun 26.
9
Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.具有突变拓扑异构酶IIα的氨吖啶耐药人白血病细胞系中拓扑异构酶IIβ缺失。
Cancer Res. 1998 Dec 1;58(23):5298-300.
10
Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.腺病毒介导的人拓扑异构酶IIα基因转移后依托泊苷敏感性增强与拓扑异构酶IIβ无关。
Br J Cancer. 2001 Sep 1;85(5):747-51. doi: 10.1054/bjoc.2001.1966.
引用本文的文献
1
Chemosensitivity to doxorubicin in primary cells derived from tumor of FVB/N-Trp53 with TALEN-mediated Trp53 mutant gene.TALEN介导的Trp53突变基因对源自FVB/N-Trp53肿瘤的原代细胞中阿霉素的化学敏感性
Lab Anim Res. 2023 Oct 20;39(1):23. doi: 10.1186/s42826-023-00175-2.
2
GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.GSDME 通过诱导视网膜母细胞瘤细胞发生细胞焦亡增加化疗药物敏感性。
Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. doi: 10.1155/2022/2371807. eCollection 2022.
3
Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression.新型长链非编码RNA 005620通过调控整合素β1（ITGB1）的表达诱导三阴性乳腺癌对表柔比星耐药。
Front Oncol. 2021 Mar 4;11:592215. doi: 10.3389/fonc.2021.592215. eCollection 2021.
4
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.晚期皮肤癌的化疗耐药机制
Oncol Rev. 2017 Mar 24;11(1):326. doi: 10.4081/oncol.2017.326. eCollection 2017 Mar 3.
5
Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.通过二氨基对甲氧基苯并咪唑（Hx）聚酰胺靶向抑制 NF-Y：DNA 结合来调节拓扑异构酶 IIα 的表达和化学敏感性。
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):617-629. doi: 10.1016/j.bbagrm.2016.10.005. Epub 2016 Oct 24.
6
RAD001 can reverse drug resistance of SGC7901/DDP cells.RAD001可逆转SGC7901/DDP细胞的耐药性。
Tumour Biol. 2014 Sep;35(9):9171-7. doi: 10.1007/s13277-014-1719-1. Epub 2014 Jun 12.
7
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.29 株乳腺癌细胞系在化疗压力下的平行进化导致了不同的耐药机制。
PLoS One. 2012;7(2):e30804. doi: 10.1371/journal.pone.0030804. Epub 2012 Feb 2.
8
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.拓扑异构酶 II 抑制剂沃利替尼可引起髓系白血病细胞的细胞周期停滞和凋亡，并与阿糖胞苷协同作用。
Haematologica. 2011 Mar;96(3):393-9. doi: 10.3324/haematol.2010.032680. Epub 2010 Dec 6.
9
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.拓扑异构酶IIβ负向调节视黄酸受体α的功能：视黄酸耐药的一种新机制。
Mol Cell Biol. 2008 Mar;28(6):2066-77. doi: 10.1128/MCB.01576-07. Epub 2008 Jan 22.
10
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.人类拓扑异构酶IIα表达的下调与在近端和远端启动子区域结合的特异性因子Sp1和Sp3的相对量相关。
BMC Mol Biol. 2007 May 20;8:36. doi: 10.1186/1471-2199-8-36.
本文引用的文献
1
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Int J Cancer. 1999 Mar 1;80(5):744-50. doi: 10.1002/(sici)1097-0215(19990301)80:5<744::aid-ijc19>3.0.co;2-5.
2
Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.阿霉素耐药的人胃腺癌细胞系中拓扑异构酶II活性降低。
Cancer Chemother Pharmacol. 1998;41(5):353-60. doi: 10.1007/s002800050751.
3
4
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.
Int J Cancer. 1997 May 29;71(5):817-24. doi: 10.1002/(sici)1097-0215(19970529)71:5<817::aid-ijc20>3.0.co;2-3.
5
Mechanism of action of topoisomerase II-targeted antineoplastic drugs.拓扑异构酶II靶向抗肿瘤药物的作用机制。
Adv Pharmacol. 1994;29B:105-26. doi: 10.1016/s1054-3589(08)61134-5.
6
7
Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.一种对抑制拓扑异构酶II的抗癌药物具有抗性的人类黑色素瘤细胞异常突变体的特征分析。
J Cell Physiol. 1993 May;155(2):414-25. doi: 10.1002/jcp.1041550224.
8
A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Biochemistry. 1994 Sep 20;33(37):11327-32. doi: 10.1021/bi00203a030.
9
10
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.抗肿瘤药物作用机制：4'-（9-吖啶基氨基）-间甲氧基甲磺酰苯胺对哺乳动物DNA拓扑异构酶II在DNA上的毒害作用。
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1361-5. doi: 10.1073/pnas.81.5.1361.
Zotero 插件